Review article: emerging insights into the immunopathology, clinical and therapeutic aspects of hepatitis delta virus.

Authors:
Usai C; Gill US; Riddell AC; Asselah T; Kennedy PT.

Journal:
Aliment Pharmacol Ther

Publication Year: 2022

DOI:
10.1111/apt.16807

PMCID:
PMC9314912

PMID:
35292991

View on PubMed View on PMC View Publisher
Journal Information

Full Title: Aliment Pharmacol Ther

Abbreviation: Aliment Pharmacol Ther

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Gastroenterology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Related Papers from Same Journal
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic…
Wijarnpreecha K; Li F; Lundin SK and 5 more (2023) - Transparency Score: 3/6
Longer time to recovery from acute kidney injury is associated with major adverse kidney events in …
Patidar KR; Naved MA; Kabir S and 9 more (2023) - Transparency Score: 3/6
A novel phenotype-based drug-induced liver injury causality assessment tool (DILI-CAT) allows for s…
Hermann RP; Rockey DC; Suzuki A and 2 more (2022) - Transparency Score: 3/6
A retrospective cohort study: pre-operative oral enteral nutritional optimisation for Crohn's disea…
Meade S; Patel KV; Luber RP and 17 more (2022) - Transparency Score: 4/6
Chicago classification v4.0 protocol improves specificity and accuracy of diagnosis of oesophagogas…
Visaggi P; Ghisa M; Del Corso G and 11 more (2022) - Transparency Score: 3/6
View All Papers from This Journal
Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declaration of personal interests : Tarik Asselah has acted as a speaker and/or advisor board and/or investigator for Abbvie, Eiger Biopharmaceutical, Janssen, Gilead, Myr Pharmaceutical, Roche, and Merck. Patrick Kennedy has served as a speaker, a consultant/advisory board member for Aligos, Antios Therapeutics, Assembly Biosciences, Gilead Sciences, Janssen, GlaxoSmithKline, Immunocore and Drug Farm, and has received research funding from Gilead Sciences. Declaration of funding interests : None."

Evidence found in paper:

"Declaration of funding interests: None."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025